Chronic Myelogenous Leukemia Chronic Phase(CML-CP) Patients With Low Imatinib Trough Levels, CML, Philadelphia Chromosome Positive (Ph+)
Conditions
Keywords
Philadelphia chromosome positive, Ph+, chronic myelogenous leukemia chronic phase, CML-CP, low imatinib trough levels
Brief summary
This study is to determine the number of European Leukemia Network (ELN)guideline defined treatment failure events from time of study entry in CML-CP patients with low imatinib trough concentrations treated with nilotinib.
Interventions
DRUGnilotinib
All patients will receive nilotinib 300mg bid po daily. Nilotinib dose is taken every 12 hours
Sponsors
Novartis Pharmaceuticals
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Cytogenetically confirmed Ph+ CML-CP Any prior dose of Imatinib * Imatinib 400 mg daily for ≥7 consecutive days prior to imatinib trough collection * Imatinib trough plasma concentration \<850 ng/mL
Exclusion criteria
* Prior documented failure events as defined by ELN guidelines: * Loss of CHR, CCyR, or clonal progression/Ph+ * Less than CHR at 3 months after diagnosis * No CyR at 6 months after diagnosis * Less than PCyR at 12 months after diagnosis * Less than CCyR at 18 months after diagnosis * Prior accelerated phase or blast phase CML * Previously documented T315I mutation * Previous treatment for CML with any other tyrosine kinase inhibitor except for imatinib * Patients who had any other treatment for CML (transplant) except interferon +/- ara- C, imatinib, hydroxyurea and/or anagrelide * Impaired cardiac function * Patients receiving therapy with strong inhibitors of CYP3A4 or medications that prolong the QT interval and cannot be either discontinued or switched to a different medication prior to starting study drug. * Any other malignancy that is clinically significant or requires active intervention. * Major surgery within 4 weeks prior to Day 1 of study or who have not recovered from prior surgery * Treatment with other investigational agents within 30 days of Day 1 * Women who are pregnant, breast feeding, or of childbearing potential without a negative serum test at baseline. Post-menopausal women must be amenorrhoeic for at least 12 months to be considered of non-childbearing potential. Women of childbearing potential must have a negative serum pregnancy test within 7 days of the first dose of nilotinib * Sexually active male and female patients taking nilotinib unwilling to use adequate contraception throughout the trial and 3 months following discontinuation of study drug
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Treatment Failure Events up to 2 Years | up to 2 years | Treatment failure events from time of study entry in Complete molecular response-Chronic phase (CML-CP) participants with low imatinib trough concentrations less than 850 nanogram per milliliter (\<850 ng/mL) treated with nilotinib as defined in European LeukemiaNet (ELN)-guideline. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Loss of Complete Cytogenetic Response (CCyR), Major Molecular Response (MMR) and Complete Molecular Response (CMR) on Nilotinib | up to 2 years | Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as CCyR at 12 cycles if the patient met the CCyR criteria at the Cycle 12 Visit. Major molecular response is defined as values equal or below 0.1% on the International Scale. Complete Molecular Response is defined as a Bcr-Abl (a fusion of gene of Bcr and ABl genes) ratio ≤0.0032% on the International Scale Bcr = breakpoint cluster gene Abl = abelson proto-oncogene. |
| Duration of Complete Cytogenetic Response (CCyR), Major Molecular Response (MMR) and Complete Molecular Response (CMR)Achieved on Nilotinib | up to 2 years | Durations of major/complete cytogenetic response is defined as the time from the first documentation of the major/ complete response to the first documentation of the disease progression. |
| European LeukemiaNet (ELN)-Defined Optimal Responses | up to 2 years | — |
| European LeukemiaNet (ELN)-Defined Suboptimal Events | up to 2 years | — |
| Number of Participants Reported Adverse Events | Up to 2 years | An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury. |
| Event-free Survival (EFS), Progression-free Survival (PFS) and Overall Survival (OS) up to 2 Years | up to 2 years | Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following events on study treatment: loss of complete hematological response, confirmed loss of complete cytogenetic response (CCyR), confirmed loss of major molecular response (MMR), death from any cause during treatment, progression to the accelerated phase or blast crisis of chronic myelogenous leukemia (CML) per European Leukemia Network (ELN) criteria, whichever was earliest. Progressions free survival is defined as time between Day 1 cycle 1 and time to first documented disease progression or death. Disease progression will be determined as per response criteria. Overall survival time is defined as the time from the treatment start to the date of death due to any reason. |
Countries
United States
Participant flow
Recruitment details
The study was conducted at 3 centers in the United States.
Pre-assignment details
A total of 3 participants were enrolled in the study, of which 1 discontinued the study due to Adverse Event (AE) and 2 participants discontinued as the study got terminated.
Participants by arm
| Arm | Count |
|---|---|
| Nilotinib Participants received nilotinib 300 mg, BID po, every 12 hours in continuous 28-day cycle up to 2 years. | 3 |
| Total | 3 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Adverse Event | 1 |
| Overall Study | The participants discontinued the study as the study got terminated | 2 |
Baseline characteristics
| Characteristic | Nilotinib |
|---|---|
| Age, Categorical <=18 years | 0 Participants |
| Age, Categorical >=65 years | 0 Participants |
| Age, Categorical Between 18 and 65 years | 3 Participants |
| Race/Ethnicity, Customized Caucasian | 3 Participants |
| Sex: Female, Male Female | 0 Participants |
| Sex: Female, Male Male | 3 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 3 |
| other Total, other adverse events | 2 / 3 |
| serious Total, serious adverse events | 0 / 3 |
Outcome results
Primary
Number of Treatment Failure Events up to 2 Years
Treatment failure events from time of study entry in Complete molecular response-Chronic phase (CML-CP) participants with low imatinib trough concentrations less than 850 nanogram per milliliter (\<850 ng/mL) treated with nilotinib as defined in European LeukemiaNet (ELN)-guideline.
Time frame: up to 2 years
Population: The overall number of participants considered for analysis was 0 due to the premature termination of the study and low enrollment; The efficacy and quality of life assessments were not collected and reported in the study.
Secondary
Duration of Complete Cytogenetic Response (CCyR), Major Molecular Response (MMR) and Complete Molecular Response (CMR)Achieved on Nilotinib
Durations of major/complete cytogenetic response is defined as the time from the first documentation of the major/ complete response to the first documentation of the disease progression.
Time frame: up to 2 years
Population: The overall number of participants considered for analysis was 0 due to the premature termination of the study and low enrollment; The efficacy and quality of life assessments were not collected and reported in the study.
Secondary
European LeukemiaNet (ELN)-Defined Optimal Responses
Time frame: up to 2 years
Population: The overall number of participants considered for analysis was 0 due to the premature termination of the study and low enrollment; The efficacy and quality of life assessments were not collected and reported in the study.
Secondary
European LeukemiaNet (ELN)-Defined Suboptimal Events
Time frame: up to 2 years
Population: The overall number of participants considered for analysis was 0 due to the premature termination of the study and low enrollment; The efficacy and quality of life assessments were not collected and reported in the study.
Secondary
Event-free Survival (EFS), Progression-free Survival (PFS) and Overall Survival (OS) up to 2 Years
Event-free survival was defined as the time from the date of randomization to the date of first occurrence of any of the following events on study treatment: loss of complete hematological response, confirmed loss of complete cytogenetic response (CCyR), confirmed loss of major molecular response (MMR), death from any cause during treatment, progression to the accelerated phase or blast crisis of chronic myelogenous leukemia (CML) per European Leukemia Network (ELN) criteria, whichever was earliest. Progressions free survival is defined as time between Day 1 cycle 1 and time to first documented disease progression or death. Disease progression will be determined as per response criteria. Overall survival time is defined as the time from the treatment start to the date of death due to any reason.
Time frame: up to 2 years
Population: The overall number of participants considered for analysis was 0 due to the premature termination of the study and low enrollment; The efficacy and quality of life assessments were not collected and reported in the study.
Secondary
Loss of Complete Cytogenetic Response (CCyR), Major Molecular Response (MMR) and Complete Molecular Response (CMR) on Nilotinib
Complete Cytogenetic Response (CCyR) is defined as 0% of Ph+ metaphases. A patient was counted as CCyR at 12 cycles if the patient met the CCyR criteria at the Cycle 12 Visit. Major molecular response is defined as values equal or below 0.1% on the International Scale. Complete Molecular Response is defined as a Bcr-Abl (a fusion of gene of Bcr and ABl genes) ratio ≤0.0032% on the International Scale Bcr = breakpoint cluster gene Abl = abelson proto-oncogene.
Time frame: up to 2 years
Population: The overall number of participants considered for analysis was 0 due to the premature termination of the study and low enrollment; The efficacy and quality of life assessments were not collected and reported in the study.
Secondary
Number of Participants Reported Adverse Events
An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury.
Time frame: Up to 2 years
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Nilotinib | Number of Participants Reported Adverse Events | 2 Participants |